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Abstract
Background: Deregulation of platelet-derived growth factor (PDGF) signaling is a hallmark of malignant glioma. Two
alternatively spliced PDGF-A mRNAs have been described, corresponding to a long (L) and a short (S) isoform of PDGF-A. In
contrast to PDGF-A(S), the PDGF-A(L) isoform has a lysine and arginine rich carboxy-terminal extension that acts as an
extracellular matrix retention motif. However, the exact role of PDGF-A(L) and how it functionally differs from the shorter
isoform is not well understood.
Methodology/Principal Findings: We overexpressed PDGF-A(L) as a transgene under control of the glial fibrillary acidic
protein (GFAP) promoter in the mouse brain. This directs expression of the transgene to astrocytic cells and GFAP
expressing neural stem cells throughout the developing and adult central nervous system. Transgenic mice exhibited a
phenotype with enlarged skull at approximately 6-16 weeks of age and they died between 1.5 months and 2 years of age.
We detected an increased number of undifferentiated cells in all areas of transgene expression, such as in the
subependymal zone around the lateral ventricle and in the cerebellar medulla. The cells stained positive for Pdgfr-a, Olig2
and NG2 but this population did only partially overlap with cells positive for Gfap and the transgene reporter. Interestingly,
a few mice presented with overt neoplastic glioma-like lesions composed of both Olig2 and Gfap positive cell populations
and with microvascular proliferation, in a wild-type p53 background.
Conclusions: Our findings show that PDGF-A(L) can induce accumulation of immature cells in the mouse brain. The strong
expression of NG2, Pdgfr-a and Olig2 in PDGF-A(L) brains suggests that a fraction of these cells are oligodendrocyte
progenitors. In addition, accumulation of fluid in the subarachnoid space and skull enlargement indicate that an increased
intracranial pressure contributed to the observed lethality.
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Introduction
The family of platelet-derived growth factor (PDGF) includes
four different polypeptides: PDGF-A, -B, -C and -D, encoded by
four different genes [1]. Difference in structure and proteolytic
processing places these ligands into two subfamilies: PDGF-A and
-B constitutes one subfamily, and PDGF-C and –D a second
subfamily [2]. PDGF-A affects cell proliferation, survival,
migration and differentiation by way of paracrine or autocrine
interaction with the cell surface protein tyrosine kinase receptor
PDGFR-a [1,2,3]. The gene organization of PDGFA and PDGFB
includes seven exons. Exon number 6 in both PDGFA and –B
encodes a highly basic stretch of 18 amino acids with a high
proportion of lysine and arginine at the carboxy-terminus. This
positively charged retention motif can associate with heparin/
heparan sulfate proteoglycans of the extracellular matrix [4].
PDGF-A exists as two isoforms corresponding to a long (L) and a
short (S) form due to alternative splicing of exon 6 [5].
Consequently, PDGF-AL has a basic carboxy-terminal tail
encoded by exon 6, attaching it to the extracellular matrix
whereas PDGF-AS is freely diffusible in the extracellular fluid since
it lacks this retention motif [3,6].
The role of the basic extension in PDGF-AL and how it makes the
long form functionally different from the short remain unknown,
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though the significance of this motif is indicated by the fact that it is
highly similar to a corresponding sequence in PDGF-B. A similar
structural motif has also been found in placental growth factor
(PlGF) [7] and in the longer splice variants of vascular endothelial
growth factor (VEGF) [8], which are potent mitogens for
endothelial cells and structurally related to PDGF. Importantly,
the basic stretch of amino acids in PDGF-AL is evolutionary
conserved between frog, mouse and man [9,10]. Expression of the
long form of PDGF-A was originally identified in tumor cells
[5,11,12], and PDGF-AL was cloned from a human glioma cell line
[11]. The presence of mRNA encoding the long PDGF-A form in
tumor cells led to the suggestion that it might be an important
component of the transformed phenotype in some cells. By now it is
known that the short and long forms of PDGF-A transcripts are
expressed in a variety of normal tissues, such as liver, kidney and
thymus, although the short form of PDGF-A is predominant in
heart, muscle and brain [13,14]. Interestingly, PDGF-AL appears
not to be present in the retina [15] or spinal cord [16].
A number of genetically modified mouse lines with gain- and
loss-of-function mutations in Pdgf and Pdgf receptor genes have
been created in order to understand PDGFs physiological
functions. Phenotype analyses of knockout mice have demonstrat-
ed the important role of PDGFs and PDGF receptors during
embryonic development [17]. The Pdgfa knockout is invariably
lethal, but displays a range of time points of lethality, spanning
from embryonal day (E)10 to postnatal day (P)60 [17,18]. Further
analysis of Pdgfa null mice supported the findings from in vitro
studies, suggesting a role for PDGF-A as a mitogen for
oligodendrocyte progenitors [19,20,21]. Postnatally surviving Pdgfa
knockout mice develop tremor due to severe hypomyelination of
the neuronal projections within the CNS [22], while overexpres-
sion of PDGF-AS in the developing CNS instead leads to
hyperproliferation of oligodendrocyte progenitors (OPs) [16].
Even though the importance of PDGF-A and its receptor
PDGFR-a has been well described in the above mentioned
studies, these investigations did not distinguish between the
individual PDGF-A isoforms. To further investigate the function
of the long form of PDGF-A in vivo, we have derived a transgenic
mouse model overexpressing PDGF-AL under control of the
human glial fibrillary acidic protein (hGFAP) promoter. This
promoter is active in mouse embryonic brain already from day
E9.5 in the telencephalon and cerebellar region, with an activity
peak around birth. The hGFAP promoter remains active
throughout mouse adult life in astrocytic cells of the entire brain
and particularly in astrocytes of the glia limitans and in Bergman
glia of the cerebellum [23]. Neural stem cells in the subventricular
zone of the forebrain and in the subgranular zone of the dentate
gyrus in hippocampus display astrocytic characteristics by Gfap
expression and Gfap promoter activity [24,25,26,27]. Therefore,
by using this promoter, we are introducing PDGF-AL also into the
neural stem cell niches of developing and adult mouse brains. We
found that PDGF-AL similarly to the short form can induce
abnormal accumulation of cells in the mouse brain. However, the
increased cell numbers were not adjusted with time, leading to
glioma-like lesions in 4 out of 22 histologically analyzed brains and
to lethality. We also observed accumulation of fluid in the
subarachnoid space and enlargement of the skull indicating an
increased intracranial pressure contributing to early death.
Materials and Methods
Generation of transgenic mice
Transgenic mice were generated essentially in the same way as
described previously [28]. A 1.8 kb human GFAP 59 promoter
fragment [23] was used to overexpress human PDGF-AL
(GI197333758) in the mouse brain (Figure 1). The IRESbGEO
vector [29] was a backbone for the hGFAPp-PDGFAL-IRESb-
GEO construct. The plasmid IRESbGEO consists of an internal
ribosome entry site, followed by a lacZ-neoR (bgeo) fusion cDNA
and polyadenylation signal, and was modified by introduction of a
unique AscI site at the 39 end of the polyadenylation signal. The
hGFAP promoter - PDGF-AL cDNA fragment with a 59 AscI site
was prepared and inserted at the unique NotI site in the modified
IRESbGEO. All the steps in design of the construct IRES-bGEO
(hGFAPp,PDGF-AL) were verified by enzyme cleavage and
sequencing. Functional testing was performed in vitro by plasmid
transfection followed by PDGF-AL and b-galacatosidase (b-gal)
protein detection (data not shown). Transgenic mice were
generated by standard oocyte injection of the fragment excised
with AscI, isolated by agarose gel electrophoresis and purified over
Qiagen columns (Qiagen, Valencia, CA). The purified DNA was
diluted to a final concentration of 2.0 mg/ml in microinjection
buffer (10 mM Tris-HCl pH 7.3, 0.1 mM EDTA), and injected
into the male pronucleus of fertilized eggs from F1 (B6CBA) x F1
(B6CBA) mice (Bommice, Denmark) at the Karolinska Center for
Transgene Technologies (KCTT). Transgenic founders were
identified by PCR amplification of the unique hPDGF-AL
sequence in tail biopsies. DNA was extracted from tail biopsies
of three week old mice in lysis buffer (10 mM Tris-HCl, 5 mM
EDTA, 0.2% SDS, 200 mM NaCl) containing 100 mg/ml
proteinase K, and incubated at 55uC over night. The following
primers for unique hPDGF-AL were used: 59 GAT ACC TCG
CCC ATG TTC TG 39 (forward) and 59 CTG ACT CCC TAG
GCC TTC C 39 (reverse) resulting in a product with the size of
561 bp. The fragment was amplified by 10 cycles of the following
incubations: 95uC for 1 minute, 60uC for 3 minutes and 72uC for 2
minutes, followed by another 30 cycles of incubations: 95uC for 1
minute, 60uC for 1 minute, and 72uC for 2 minutes. The product
was visualized by electrophoresis in 0.8% agarose.
Detection of transgene expression
Expression of transgenic protein was detected in brains from
newborn mice using X-gal staining to detect activity of the b-gal
reporter. Brains were dissected from mice (sacrificed using CO2),
washed in PBS, fixed in 2% paraformaldehyde (PFA) in PBS at
room temperature for one hour, permeabilized in (2 mM MgCl2,
0.02% NP40, 0.01% Na-deoxycholate in PBS), and stained in
(2 mM MgCl2, 0.02% NP40, 0.01% Na-deoxycholate, 5 mM
K4Fe(CN)6, 5 mM K3Fe(CN)6 in PBS with 1 mg/ml X-gal) at
37uC for a few hours. Stained brains were washed in PBS,
dehydrated twice in methanol, and cleared in BABB (benzyl
alcohol/benzyl benzoate 1:2) for photography [30]. Transgene
activity was also studied using immunohistochemistry (IHC) for b-
gal.
Ethics statement
All animal experiments have been approved by the local ethical
committee for animal experimentation (Stockholms Norra Djur-
fo¨rso¨ksetiska Na¨mnd) under the ethical approvals N85/02, N81/
05 and N110/08.
Survival analysis
The mice were kept in a mixed CBA/C57/Bl6 background and
were followed for up to 18 months and carefully monitored. Mice
that survived for more than 6 weeks were used for breeding and all
crossings were kept hemizygous. Non-transgenic littermates were
used as controls. Mice were sacrificed upon signs of obvious
physical changes in the shape of their skull or changes in behavior
Effects of PDGF-A Long Isoform in the Mouse Brain
PLoS ONE | www.plosone.org 2 April 2011 | Volume 6 | Issue 4 | e18303
and motor functions. All mice were further subjected to necropsy
and all major organs inspected and collected for histology if
abnormal in any way. Brains were collected for histological
analysis but unfortunately not every brain was suitable for
histological analysis, as some of the mice were found dead
unexpectedly in the beginning of the study. Among 26 collected
PDGF-AL transgenic mouse brains, 4 were not suitable for
histological analysis due to severe post mortem effects. Brains were
analyzed and rated according to the extent of abnormal cell
accumulation using personal grading by the authors as follows: ‘‘-’’
- no extra cells; ‘‘+’’ – low number; ‘‘++’’ – high; ‘‘+++’’ – very
high (Table S1). Statistica program (StatSoft) was used to compare
survival of the transgenic and wild type mice in the Kaplan-Meier
diagram. The t-test for equality of means was used to calculate the
statistical significance of any mean litter size and sex ratio changes.
Immunohistochemistry
Brain tissues from transgenic and wild type (wt) control mice
were dissected and fixed in 4% PFA over night, transferred to 70%
ethanol, dehydrated and paraffin embedded. They were then
sectioned at 5 mm and stained with Hematoxylin-Eosin or used for
IHC. We regularly used automated stainings in Ventana
Discovery Automated Stainer following vendor’s suggestions
(Ventana Medical Systems, Tucson, Arizona). Briefly, deparaffi-
nization was done in the Ventana machine and heat-induced
epitope retrieval in Tris-Borate EDTA buffer pH 8.0 was used for
the antigens. A streptavidin-biotin horseradish peroxidase based
DAB kit provided by Ventana was used for detection of single
antibody stainings. Slides were subjected to graded ethanol rinses,
cleared in Xylene and mounted in Pertex. For double stainings of
b-gal and different progenitor cell markers as well in the case of co-
staining Gfap and Olig2, the sections were deparaffinized and
subjected to heat-induced epitope retrieval as above. Antigens
were sequentially detected, first with a streptavidin-biotin
horseradish peroxidase based DAB kit and second using a
streptavidin-alkaline phosphatase based kit employing NBT/BCIP
(BlueMapKit). Slides were in some cases counterstained with
Nuclear Fast Red as indicated in the figure.
Analysis and documentation of immunohistochemistry
results
The IHC stainings were analyzed microscopically and digital
photographs were obtained using an Olympus BH2 Microscope
equipped with a Leica DF320 camera. Images were assembled in
Adobe Photoshop. Comparisons of the numbers of brain cells
stained positive for Pdgfr-a, Sox2, Olig2, Gfap and Ki67 in the
different genotypes were done by counting the numbers of stained
cells in each anatomical region of interest and using at least three
brains per genotype. Due to differences in cell density between wt
and transgenic mice the numbers of immunoreactive cells were
usually expressed as a fraction (in percent) of all cells in the selected
area(s). When applicable, the t-test for equality of means was used
Figure 1. Detection and validation of transgene expression. (A) The hGFAPp-PDGFAL-IRES-bGeo construct as depicted in a schematic
drawing. (Abbreviations: hGFAPp, human glial fibrillary acidic protein promoter; hPDGFAl, human platelet-derived growth factor A long; IRES, internal
ribosome entry site; bGEO, beta-galactosidase/neomycine fusion; pA, polyadenylation signal.) (B) Results from PCR using genomic DNA from mouse
tail biopsies (transgenic line, AL8) and primers for human PDGF-AL, resulting in a 561 base pair fragment. PCR primers unique for PDGF-AL are situated
in a way that the reverse primer corresponds to a sequence in exon 6, which is only present in PDGF-AL, not -AS. Controls are the hGFAPp-PDGFAL-
IRES-bGEO construct (pAL) and DNA from wild type (wt) tails. (C) Whole mount X-gal staining of P0 transgenic and wt brains reveals activity of the
transgene on the brain surface (blue color). (D–F) Presence of the b-galactosidase (b-gal) reporter in the transgenic mouse brain compared to a wt
brain as visualized by IHC (brown color). A higher magnification image (F) reveals the individual b-gal+ cells, here exemplified by cells in a section
from the temporal lobe of a transgenic mouse brain (40x obj.).
doi:10.1371/journal.pone.0018303.g001
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to calculate the statistical significance of differences in mean cell
numbers. A p-value of ,0.05 was considered to reflect a
significant difference.
Antibodies
Primary antibodies were rabbit anti-bacterial b-gal (ab616)
(Abcam) (1:500), rabbit anti-cow GFAP (DAKO) (1:500), rabbit
anti-mouse NG2 (Millipore) (1:500), rabbit anti-mouse Olig2
(AB9610) (Millipore) (1:100), mouse anti-rat Nestin (clone rat401)
(BD Bioscience) (1:100), mouse anti-rat neuronal bIII-tubulin
(clone Tuj1) (Babco) (1:500), mouse anti-human CNPase (clone
11-5B) (Sigma Aldrich) (1:200), rabbit monoclonal anti-Ki67
(clone Sp6) (Abcam) (1:100), rabbit anti-human PDGFR-a (Cell
Signaling #3164) (1:100), rabbit anti-human PDGFR-b (Cell
Signaling #3169) (1:50), mouse anti-rat Map2 (HM-2) (1:1000)
(Sigma Aldrich), mouse anti-NeuN (clone A60) (Millipore) (1:200),
rabbit anti-Sox2 (Millipore) (1:500), rabbit anti-Calbindin-D-28-K
(EG-20) (Sigma Aldrich) (1:2000) and rabbit anti-human cleaved
Caspase-3 (Asp175) (Cell Signaling #9664) (1:300). Secondary
biotinylated antibodies included swine anti-rabbit IgG (Dako)
(1:500), donkey anti-rat IgG (1:500), and donkey anti-mouse IgG
(1:500) (Jackson Immuno-Research).
Results
PDGF-AL transgenic mice die at the median age of 120
days
To further explore PDGF-AL function in the embryonic and
adult brain, we generated transgenic mice in which expression of
PDGF-AL under control of the GFAP promoter was targeted to
astrocytic cells of the developing and adult brain. Pronuclear
injections of the hGFAPp-PDGFAL-IRESbGEO construct
(Figure 1A) resulted in 5 transgenic founders. First, we used
PCR analysis of DNA from tail biopsies to confirm the presence of
the transgene (Figure 1B). Second, whole mount X-gal staining of
brains verified activity of the transgene in one of five transgenic
lines (line 8, AL8), with strong staining over the whole surface of
the brain after birth (Figure 1C) and identical to results from
hGFAPpLacZ reporter mice [23]. Third, sections from the brains
were analyzed for transgene expression by IHC for b-gal
demonstrating strong expression of the transgene in scattered cells
all around the brain (Figure 1D-F). Particularly strong expression
was seen in the ventricular wall (especially in the roof of the lateral
ventricles), in corpus callosum, on the outer surface of the brain
(glia limitans), and in the cerebellum (Figure 1E). No b-gal
immunoreactivity was detected in wt brains. Another pronuclear
injection was performed to create more PDGF-AL overexpressing
transgenic mice and confirm the observed phenotype. Founder
#12 was found to possess the active transgene and b-gal staining
of this mouse brain showed moderate transgene activity (data not
shown).
PDGF-AL transgenic mice of line 8 were fertile and their
offspring were vital at birth until the approximate age of one and a
half month after which most of these mice developed significant
skull enlargement and died (Figure 2A). Importantly, the founder
#12 died at the age of 4 months with the same brain phenotype as
line 8 mice. A systematic survival analysis was performed including
26 transgenic mice and non-transgenic wt mice, which were
Figure 2. PDGF-AL transgenic mice die from abnormalities in the brain. (A) Skull enlargement as exemplified in PDGF-AL transgenic mice of
line 8 (AL8). Compared to wt littermate controls there was an abnormal increase in the amount of fluid in the subarachnoid space situated between
the brain surface and the skull in transgenic mice. (B) Kaplan-Meier survival curve showing the life span of transgenic mice that included data from 25
mice of line #8 and the founder mouse #12.
doi:10.1371/journal.pone.0018303.g002
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monitored on a daily basis. 25 of the 26 PDGF-AL mice died or
were sacrificed due to neurological symptoms and/or to skull
enlargement with the overall median survival time of 120 days
(Figure 2B). Founder of line 8, survived more than two years and
was sacrificed due to old age. It was observed to have an atrophic
cerebellum with thin granular layer (Table S1). Necropsy of mice
from PDGF-AL line 8 revealed an abnormal retention of fluid
in the subarachnoid space between the brain surface and the skull.
In addition, the pressure from this fluid resulted in deformation of
the skull bones and made the surface of the brain become
smooth, giving the brain an unusually compressed and thin shape
(Figure 2A). All major organs of all the animals in this study were
further examined and no abnormalities other than in the brain
were found.
The reproductive ability of PDGF-AL line 8 mice was compared
to C57/Bl6 breeding couples. Line 8 (16 litters) showed no
difference in mean litter size compared to wt breeding couples, 6.4
versus 7.6 pups per litter (p.0.05). The ratio between the number
of transgenic progeny and the number of non-transgenic was
47.2% (p.0.05), hence no indication of embryonic lethality. We
observed a slight difference in the sex ratio of progeny from the
PDGF-AL transgenic line 8 compared to the expected 1:1 ratio in
Figure 3. Increased cellularity in PDGF-AL brains. An overview of coronal sections of a PDGF-AL transgenic mouse brain (AL8 line, #4012) and
wt littermate control (H&E staining). Higher magnification images in lower panels of selected areas from the overviews serve to illustrate areas of
increased cellularity (20x and 40x objectives, respectively). A rather loose texture of the accumulating ‘‘clear’’ cells is indicated with arrows in pia and
cerebellum. Strikingly, the borders of the inner granular layer in cerebellum appeared to be diffuse compared to wt control brain. Abbreviations: Hp-
hippocampus, CC-Corpus callosum, SVZ- subventricular zone, Cblm – cerebellum.
doi:10.1371/journal.pone.0018303.g003
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the hemizygous crossings. Sixteen litters were analyzed and there
was a statistically significant but still relatively small increase in the
number of male mice among the transgenic progeny (60% males
versus 40% females, p,0.05, transgenic mice n= 50). Breeding of
the founder mouse #12 with C57/Bl6 mice did not result in
transgenic progeny.
Locally increased cellularity in the brains of PDGF-AL
transgenic mice
Brains from PDGF-AL and wt mice were further analyzed by
routine histology. Sagittal and coronal sections stained with
Hematoxylin-Eosin revealed areas with highly increased cellularity
in the wall and especially the roof of lateral ventricles and their
position was mostly subependymal (Figure 3). These cells were
characterized by their clear cytoplasm and small, rounded nuclei
and hence based on this morphology we denoted them as ‘‘clear
cells’’. These cells are shown in greater detail in Figure 4. In some
sections, a fraction of the cells were seen breaking into the ventricle
through the ependyme, leading to seeding of cells on the
ventricular lining, even as far as the 4th ventricle. A majority of
the mice that died or were sacrificed due to symptoms displayed
locally increased cellularity in the brain although in varying
amounts and distribution (Table S1). In most of the brains, the
abnormal cells were also found within the corpus callosum and
along its extensions, in the thickened pial lining forming pial
outgrowths and in the medulla of cerebellum (Figure 3). In
cerebellum, the inner granular layer appeared diffuse and
disorganized when compared to wt brains. This was due to the
presence of ‘‘clear’’ cells expanding from the white matter into the
granular layer (Figure 3). ‘‘Clear’’ cells were also present in the
white matter of pons and the brain stem in some mice. Essentially,
the distribution of these abnormal ‘‘clear’’ cells overlapped with
the distribution of high transgene expression visualized by b-gal
IHC.
To substantiate the histological findings we counted the numbers
of all cells in one selected high magnification area corresponding to
each of the above mentioned regions from five transgenic mice
brains and compared this to the cell counts from similar areas in five
wt brains. A statistically significant increase in numbers of cells was
seen in the lateral ventricle wall, hippocampus and corpus callosum
(p,0.05 for each of these regions), whereas no significant difference
in cell number was found in the cerebellum or temporal lobe area
(p.0.05) (Figure 5A). The subgranular zone of the dentate gyrus in
hippocampus was morphologically intact, although the hippocam-
pal area as a whole, including white matter, showed an increase of
cells (data not shown).
In summary, our results demonstrate that PDGF-AL can induce
abnormal accumulations of cells in the mouse brain, similar to
what was seen when PDGF-AS was injected directly into the
lateral ventricle of mice [31]. In addition, we observed
accumulation of translucent fluid in the subarachnoid space and
skull enlargement indicating an increased intracranial pressure
contributing to the lethality of the lesions. Choroid plexus from
transgenic mice showed no changes in structure compared to wild
type mice. A slight to moderate increase in the ventricle size was
noted in a subset of the PDGF-AL transgenic mice but the
cerebrospinal-like fluid accumulated mostly in the subarachnoid
space and seemed to compress the brain from the outside.
Increased proliferative activity in the brains of PDGF-AL
transgenic mice
We next assessed the level of cell proliferation in transgenic
mouse brains by using the Ki67 antibody. Clearly, regions with
accumulating cells displayed an increased percentage of cells that
stained positive for Ki67 (Figure 5B). For instance, in the
subventricular zone (SVZ), the fraction of Ki67+ cells turned out
to be 11.665.5 (%) in transgenic mice versus 1.7362.1 (%) in wt
(n = 3/genotype; p,0.05). We could also detect more Ki67
Figure 4. Morphology of accumulating cells in the PDGF-AL brain. Light microscopy images of an H&E stained section, in low (A) and high (B)
magnification, illustrating the presence of immature cells in the roof of the lateral ventricle in a PDGF-AL transgenice mouse brain (AL8 line, #4012).
doi:10.1371/journal.pone.0018303.g004
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positive cells in the hippocampus area, in the pial outgrowths and
in cerebellum of PDGF-AL mice (Figure 5B) (Table S2). In wt
mice, a small localized area of intensively proliferating cells was
observed in the lateral ventricular wall in a region that may
correspond to the neural stem cell niche, whereas almost no
proliferation was observed in the roof of the lateral ventricles, in
pia and cerebellum. In transgenic mice, the proliferating cells were
widely scattered in the roof of the lateral ventricles which was
different from the organized pattern of Ki67-positive cells
observed in the lateral ventricular wall. We conclude that the
regions with accumulating cells in the PDGF-AL transgenic mouse
brain displayed significantly high proliferative activity.
Increased fractions of Pdgfr-a and Olig2 positive cells in
the brains of PDGF-AL transgenic mice
Immunohistochemistry was carried out using a variety of cell
type-specific markers to further characterize the nature of the
accumulated cells. We first observed that the b-gal expression was
particularly strong in areas with increased cellularity strongly
indicating that this was caused by PDGF-AL. Areas with high
expression of b-gal displayed strong Gfap expression (Figure 6A
and 6C), and both Gfap+ cells and b-gal+ cells displayed an
astrocyte-like morphology (Figure 1F). Next, we compared the
patterns of Gfap and Olig2 expression in the SVZ and pia
(Figure 6A-C). Olig2, which is present in oligodendrocyte
progenitors, and serves as a marker for human gliomas, was
increasingly expressed in areas with accumulation of cells in the
PDGF-AL brains (Figure 6B and 6C). Also the pial proliferations
consisted of Gfap+ as well as Olig2+ cells indicating their neural
character (Figure 6C). A significant increase in the number of
Olig2+ cells was seen in cerebellum and hippocampus of
transgenic mice (p,0.05) (Figure 5C) but the difference in Olig2+
cells between wt and transgenic mice did not reach statistical
significance in SVZ and corpus callosum. However, when all the
selected areas were taken together, 46.265.1 (%) of cells were
Olig2+ in transgenic mice compared to 27.761.4 (%) Olig2+ cells
in wt mice (n = 3/genotype; p,0.05). The mature oligodendrocyte
protein CNPase was not expressed in the accumulating cells and
Figure 5. Quantification of cell numbers and of cells expressing different lineage markers in brain areas with increased cellularity.
(A) Quantification of total cell numbers in hippocampus (Hp), subventricular zone (SVZ), corpus callosum (CC), temporal lobe area (TL), and
cerebellum (Cblm). The counting is based on the comparison of one high power field (40x obj.) from each anatomical region in transgenic (AL8) and
wt mice. Mean and standard error of the mean is presented for 5 transgenic mice (AL8) and 5 wt mice. Differences at p,0.05 were considered
significant and are marked with (*). Given that the protruding lesions in Pia did not have a corresponding wt area to count it was excluded from the
analysis (a.u = area unit). (B–F) Frequencies of Ki67, Olig2, Pdgfr-a, Sox2, and Gfap immunoreactive cells in wt and transgenic mice. Quantification was
based on the counting of both the total number of cells and positively stained cells for each individual marker in one high power field (40x obj.).
Mean and standard error of the mean is presented for 3 transgenic mice (AL8) and 3 wt mice. Differences at p,0.05 were considered significant and
are marked with (*). P-values,0.01 are marked with (**).
doi:10.1371/journal.pone.0018303.g005
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stainings for neuronal lineage differentiation markers such bIII-
tubulin and Map2 were mostly negative. We noticed that the
subgranular zone cells of the dentate gyrus in hippocampus
strongly expressed both the transgene and Gfap, but in the
absence of any histological abnormality in this area (data not
shown).
We analyzed the sections further by staining for Pdgfr-a. Of
note, Pdgfr-a is normally expressed by cells in the meninges and
by many tissues outside the CNS [32]. This explains some of the
positive staining seen in wt tissue in the meninges. In the wt
mouse brain, Pdgfr-a was also present on scattered cells in the
brain stem presumably representing normal oligodendrocyte
progenitors. In the transgenic mice, we found an increased
Pdgfr-a staining, and positive cells were frequently scattered
around the brain with strong signals in the regions with increased
cell numbers (Figure 6B and 6C). For instance, the frequency of
Pdgfr-a+ cells in the SVZ of transgenic mice was 34.3613.5 (%)
versus 5.462.2 (%) in wt mice (n = 3/genotype; p,0.05)
(Figure 5D). Next we carried out IHC for detection of the
putative neural progenitor cell marker protein Sox2 (Figure 7).
Scattered Sox2+ cells could be seen in regions of increased
cellularity and were significantly more frequent in the SVZ of
transgenic mice, namely 66.9611.2 (%) in transgenic mice
compared to 14.7613.6 (%) in wt mice (n = 3/genotype;
p,0.05). Indeed, in a wt mouse the thin line of Sox2+ cells
was more strictly ependymal (Figure 7). Sox2+ cells were also
detected in the pial outgrowths of the transgenic mice (Figure 7).
Abnormal morphology of the cerebellum
Special attention was given to the morphology of the cerebellum
in order to determine the amplitude of disruption caused by
PDGF-AL. As mentioned, the structure of the cerebellum was
deformed when compared to wt mice (Figure 3). Using the
markers NeuN for mature granule cells and Calbindin for Purkinje
cells we could determine that the layers of the cerebellar cortex
maintained their correct order in relation to each other, but due to
the expansion of abnormal cells into the inner granular layer this
became disintegrated (Figure 8A). In addition, IHC for b-gal, Gfap
and Olig2 showed strong positivity in the cerebellum of transgenic
mice (Figure 8C) and this was confirmed by cell counting (Figure 5
and Table S2). For instance, the frequency of Olig2+ cells per unit
area in cerebellum of transgenic mice was a remarkable
44.563.4% when compared to only 3.862.6 (%) in wt mice
(n = 3/genotype; p,0.05) (Figure 5C). In addition, the fractions of
Pdgfr-a+ and Sox2+ cells were increased (Figure 5D and 5E). Of
note is the distinct 1-2 cell layer thick band of well-organized
Sox2+ cells at the level of Purkinje cell bodies observed in wt
brains but not in transgenic mice, further illustrating the
disintegrated structure of cerebellum (Figure 8B). Finally, Pdgfr-
b IHC revealed an increased amount of capillary vessels especially
in the cerebellum of the transgenic mice compared to wt
littermates (Figure 8D). The vascular structures were thick-walled
compared to that seen in wt mice. In comparable sections of the wt
brains, Pdgfr-b was present only on a few discrete cells, viz
pericytes tightly associated with capillary vessels.
Figure 6. Presence of different lineage marker proteins in brain areas with increased cellularity. (A) IHC for b-gal and Gfap in the SVZ
from an AL8 mouse (#4012). The stainings revealed strong expression of the transgene (b-gal marker) and the location of Gfap
+ astrocyte-like cells
matched the expression of b-gal in parallel sections. Corresponding SVZ areas are shown for wt control brain (40x obj.). (B) Presence of Olig2 positive
and Pdgfr-a positive cells in the SVZ (40x obj.) (C) IHC for b-gal, Gfap, Olig2 and Pdgfr-a in a pial lesion of a transgenic mouse of line AL8 (#4016).
Abbreviation: SVZ-subventricular zone.
doi:10.1371/journal.pone.0018303.g006
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The abnormal cell populations in areas of transgene
expression constitute in part Pdgfr-a positive precursors
with similarities to oligodendrocyte progenitors
Oligodendrocyte progenitors usually co-express Pdgfr-a, the
transcription factor Olig2 and the neuroglial chondroitin sulfate
proteoglycan NG2. To further investigate the nature of the
additional cells in transgenic mice we carried out a series of co-
stainings by IHC for b-gal in combination with Olig2, Pdgfr-a or
NG2, as well as co-stainings for Gfap and Olig2. Interestingly, as
is here exemplified with the SVZ in the roof of the lateral
ventricle, there was an evident non-overlap between b-gal
expressing cells and those cells that stained positive for Olig2,
NG2 or Pdgfr-a, respectively (Figure 9A–C). We estimated the
fraction of b-gal+ cells that were co-expressing Olig2 by
analyzing and counting cells in high power magnification fields.
The predominant nuclear Olig2 staining made it most suitable
for this analysis. In the SVZ on average 50620 (%) of b-gal+ cells
expressed Olig2 (tg mice: n = 3). Moreover, only ,30610 (%) of
the b-gal+ cells in hippocampus expressed Olig2 (tg mice: n = 3).
Similarly, the numbers of cells co-expressing b-gal and Pdgfr-a in
the SVZ and hippocampus was only on ,10% in each location.
In support of the notion that cells expressing the transgene might
be a different population of cells than those expressing Olig2
and/or Pdgfr-a we found that the fraction of Gfap+ cells that co-
expressed Olig2 was only ,1064 (%) in the SVZ, and ,1067
(%) in the hippocampus (tg mice: n = 3) (Figure 9D). In
conclusion, the IHC analyses revealed that a substantial fraction
of the accumulated cells most likely represent oligodendrocyte
progenitors that stain positive for Pdgfr-a, Olig2 and NG2. These
cells were mostly different from, but intimately mixed with, the
astrocytic, transgene expressing cells.
The most extensive brain lesions display features of neoplasia
Four of the transgenic brains showed more extensive lesions.
As exemplified with the worst case (mouse #4000) there was a
heavy diffuse infiltration of cells in virtually the whole brain,
encompassing most white matter areas including the hippocam-
pal and cerebellar outer layers and this was associated with
abundant, angulated and thick-walled capillary structures
(Figure 10A). The pial proliferations were extensive, forming cell
rich lumps with obvious mitotic (Figure 11) and abnormal cells
(Figure 10C), in a few areas with a bluish tint and microcystic
fluid accumulations. Where these lumps were present on the pial
surface the glia limitans was disrupted (Figure 10C). Also the
temporal lobe was especially cell-rich, with a localized area of
cells carrying uneven, multi-lobulated nuclei and at the same time
a local increase in Gfap, Olig2 and Pdgfr-a positive cells
(Figure 10B) (Table S2). Stainings for Map2 and bIII-tubulin
revealed only sparse, dislocated neuronal cells in the same area
(data not shown). Moreover, staining for Ki67 revealed massive
proliferation in this mouse brain in several different anatomical
regions (Figure 11) (Table S2). Locally, in the neoplasia-like area
of the temporal lobe, the Ki67 labeling index was as high as 53%,
whereas it was only 1.4% in the corresponding area from a wt
Figure 7. Sox2 positive cells in the areas with increased cellularity. Presence of Sox2+ cells in different regions of a transgenic mouse brain
(AL8, # 4012), as shown in the upper two panels in low (20x obj.) and high magnification (40x obj.), respectively. Shown are also corresponding
regions in a wt brain in the lower two panels (20x and 40x obj.). Abbreviations: Hp-hippocampus, CC-Corpus callosum, SVZ-subventricular zone.
doi:10.1371/journal.pone.0018303.g007
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brain and 1.2% in another PDGF-AL brain (Table S2). In
summary, the analysis of cells in the neoplasia-like areas revealed
accumulation of highly proliferative abnormal glial precursor cells
displaying Gfap-positivity and frequent Olig2 and Pdgfr-a
positivity coupled to a high proliferation rate. Given the
appearance of mixed glial cell phenotypes, diffuse spread and
increased vascularity these areas are similar to human oligoas-
trocytomas grade III (WHO scale).
Discussion
In this study we overexpressed PDGF-AL under the astrocyte
specific promoter for GFAP. As mentioned this promoter is active
in mature astrocytic cells as well as in neural stem cells of the
lateral ventricle wall. In the CNS, PDGF-A is normally expressed
by many neurons as well as by astrocytes [21,33,34], but these cells
are not generated in large numbers until after birth. In our study
Figure 8. Changes in the presence of different cell lineage marker proteins and in the structure of cerebellum in PDGF-AL
transgenic mice. (A) IHC for Calbindin (marker for Purkinje cells) and NeuN (marker for terminally differentiated neuronal cells, here granular cells) in
the cerebellum of the transgenic mouse AL8, #4016 (upper panel) and in cerebellum of a wt mouse (lower panel). (B) H&E staining and expression of
Sox2 in cerebellum of a transgenic brain (AL8, #4012) compared to corresponding areas in a wt cerebellum (40x obj) (C) H&E staining and IHC for b-
gal, Gfap, Olig2 and Pdgfr-a in cerebellum from a transgenic mouse (D) IHC for Pdgfr-b cerebellum of a transgenic (AL8 #4011) and a wt mouse (20x
obj.).
doi:10.1371/journal.pone.0018303.g008
Effects of PDGF-A Long Isoform in the Mouse Brain
PLoS ONE | www.plosone.org 10 April 2011 | Volume 6 | Issue 4 | e18303
we created additional sources of constant PDGF-A expression with
fatal consequences. The GFAPp-PDGF-AL mice showed a distinct
phenotype with accumulation of cells in many different locations
in the brain where the transgene was active, as well as
accumulation of a thick translucent fluid in the subarachnoid
space. The choroid plexus of the lateral ventricle produces most of
the cerebrospinal fluid [35]. Fluid is normally produced contin-
uously at a rate sufficient to fill the ventricular system together with
cranial and spinal subarachnoid spaces several times a day [35,36].
Most cases of hydrocephalus in humans are caused by blockage of
the flow of cerebrospinal fluid. The fluid fills the ventricles and
compresses the brain from within leading to a rise of the
intracranial pressure and expansion of the ventricles and [37].
Choroid plexus from PDGF-AL transgenic mice showed no
changes in structure compared to wt mice, but a slight to
moderate increase in the ventricle size was noticed in a subset of
the PDGF-AL transgenic mice. Enlarged lateral ventricles have
recently been described in transgenic mice expressing PDGF-B
under control of a minimal nestin enhancer element [38].
However, in the present mice fluid accumulated mostly in the
subarachnoid space and to the extent that it compressed the brain
from the outside. The observed accumulation of fluid together
with skull enlargement and compression of the brain indicated that
an increased intracranial pressure contributed to early death of the
animals.
In the PDGF-AL transgenic mice we detected strong expression
of Gfap in the brain, which mostly followed the same pattern as
that of b-gal (the transgene reporter), indicating that PDGF-AL
was produced by astrocytic cells. As PDGF-AL has a C-terminal
tail that helps to associate the protein with the extracellular matrix
and the surface of the producing cells [39], the PDGF-AL site of
action may be mostly limited to the secretory cell itself and its
closest neighbors. Indeed, we detected increased numbers of
Pdgfr-a carrying cells in the areas with b-gal+ cells indicating that
the introduced PDGF-AL had stimulated responsive cells. It has
previously been shown that Pdgfr-a is expressed by proliferative
and migratory glial progenitor cells, called O-2A progenitors
[40,41]. These cells originate in the ventricular and subventricular
zones of the embryonic brain and spinal cord, then proliferate and
migrate throughout the developing CNS [42]. They start to
develop into myelinating oligodendrocytes around birth, continue
to divide and differentiate during early postnatal life. At the same
time Pdgfr-a is rapidly downregulated after progenitor cells stop
dividing and start to differentiate [43]. Thus, normally the
distribution of Pdgfr-a positive cells in the embryonic and
postnatal brain reflects the distribution of O-2A progenitors,
rather than that of differentiated oligodendrocytes. During
development, O-2A numbers are limited by the supply of
PDGF-A. It was demonstrated that in mice overexpressing
PDGF-A in neurons (neuron specific enolase (NSE)-PDGF-AS
mice), the number of oligodendrocyte progenitor cells increased 7-
fold. It led to secondary overproduction of oligodendrocytes, many
of which were situated in for them abnormal locations. However,
at an early stage of development, the extra cells were all eliminated
by programmed cell death, leaving the final number and
distribution of mature oligodendrocytes within the normal range
[16]. No special phenotype of adult mice was reported in that
study. However, a phenotype in adult mice has been reported in
another study, where under control of the GFAP promoter,
PDGF-AS was found to regulate oligodendrocyte progenitor
number in adult CNS, demonstrating an increase in their number
[44], similar to what is observed here. In fact, in the transgenic
mice presented here we detected virtually no apoptotic figures
among the accumulated cells by staining for cleaved caspase-3 (not
shown), and cell numbers were in general not adjusted with time.
Our transgenic mice phenotype indicates that also PDGF-AL is a
potent factor in postnatal brain development. The results are in
accordance with other studies in which the Pdgfa gene was
disrupted [22], or in studies where PDGF-AS was overexpressed,
leading to a decreased or increased number of oligodendrocyte
progenitors, respectively [16]. However, it should be kept in mind
that expression of PDGF-AS mRNA is predominant over PDGF-
AL in the normal brain [16].
What is then the origin and significance of the extra cells found in
the brains of PDGF-AL-transgenic mice and of the neoplastic
lesions? We could consider an origin from adult neural stem or
progenitor cells which normally display astrocytic features, as well
as from oligodendrocyte progenitor cells or even astrocytes. The
strong Pdgfr-a expression in PDGF-AL brains indicates that a
fraction of the accumulating cells represent some type of
progenitors rather than mature oligodendrocytes, which is in line
with the absence of CNPase in these cells. In order to obtain
support for this possibility we stained parallel sections with Olig2
and NG2 antibodies demonstrating increased expression of these
proteins. A majority of the cells that stained positive for Olig2 or
Pdgfr-a did not express Gfap or the transgene marker. Thus, a
fraction of the accumulated cells can therefore be defined as
oligondendrocyte progenitors/O-2A progenitors. This finding is in
agreement with the known ability of PDGF-A to stimulate
expansion of oligodendrocyte progenitors. Other studies have
shown that PDGF-A can bias cell-fate decisions, for example mouse
neural progenitors residing in the SVZ are induced to become
OPCs rather than neurons in response to PDGF treatment [31].
Indeed, PDGF-A treatment delays differentiation of neural
Figure 9. Accumulated cells expressing oligodendrocyte pro-
genitor markers do not generally overlap with but are mixed
with b-gal and Gfap positive cells. (A–C) Co-immunostainings for b-
gal (brown color) with Olig2, Pdgfr-a and NG2 (blue color) respectively.
Only a fraction of the accumulated cells showed double positivity as
indicated with arrows in b-gal/Olig2 double IHC (see text for details). (D)
Co-immunostaining (IHC) of Gfap (brown) and Olig2 (blue). In D the
section was also counterstained with Fast Red dye (pink) (40x obj.). The
tissue sections represent the SVZ from AL8 mice (#4007 and #4008).
doi:10.1371/journal.pone.0018303.g009
Effects of PDGF-A Long Isoform in the Mouse Brain
PLoS ONE | www.plosone.org 11 April 2011 | Volume 6 | Issue 4 | e18303
precursors that remain in an immature state [45]. It has also been
known for quite some time that PDGF-A has a dedifferentiating
effect on Gfap expressing astrocytes [46]. Thus, PDGF-A has
profound effects on neural cell proliferation and differentiation that
may be of importance during glioma development [47].
However, we did also detect more frequent Gfap+ cells mixed
with the oligodendrocyte progenitors. Gfap expression is a
common characteristic of normal subependymal cells [48]. This
layer contains adult neuroepithelial stem cells, oligodendrocyte
and astrocyte progenitor cells [48]. The strong expression of Gfap
Figure 10. Lineage marker protein expression in brain areas with glioma-like lesions. (A) Different areas of a transgenic mouse brain with
neoplastic glioma-like lesions (AL8, #4000) as indicated (20x obj. upper panel and 40x obj. lower panel, H&E staining). (B) IHC for b-gal, Gfap and
Olig2 in the temporal lobe area of the same transgenic mouse brain as in (A). (C) IHC for b-gal, Gfap and Olig2 in the pial area of transgenic mouse
brain AL8, #4000 (20x obj. left panels and 40x obj. right panels). Abbreviations: Hp-hippocampus, CC-Corpus callosum, SVZ-subventricular zone, TL-
temporal lobe.
doi:10.1371/journal.pone.0018303.g010
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and Olig2, mostly in different cells but also infrequently in the
same cells, as well as the SVZ/subependymal location of the
abnormally accumulating cells in PDGF-AL transgenic mice
speaks in favor of their potential derivation from neuroepithelial
stem cells. One might also speculate that PDGF-AL stimulates
expansion of a Gfap+ glial progenitor/stem cell population that in
turn gives rise to progeny representing more differentiated
astrocytic cells as well as oligodendrocyte progenitors.
Interestingly, our observations support an overt neoplastic
nature of some of the lesions, as seen in ,20% (4/22) of the mice.
Cells accumulated to form lumps both within the cerebral tissue
and in pia, in these worst cases with high cell density, mitoses and
nuclear atypia as well as locally increased amounts of cells
expressing Pdgfr-a, Olig2 and Gfap. The increased proliferation
and turnover of cells was indicated by locally high Ki67 labeling
index accompanied by detectable clusters of cleaved caspase-3
positive cells. In support of our finding, it was reported that Pdgfr-
a type B cells in the SVZ can be induced to form reversible
hyperplastic glioma-like growths in response to PDGF-A infusion
in the lateral ventricle [31].
While it is undisputable that PDGF induces glioma formation in
mice it has remained debated to what extent the tumors represent
pure oligodendrogliomas [47]. Indeed, retroviral expression of
PDGF-B in newborn mice leads to oligodendroglioma-like tumors
[49], whereas expression of PDGF-A in Gfap+ cells also induces
rare mixed oligoastrocytomas in mice [46]. As another example,
the inactivation of the Retinoblastoma tumor suppressor (Rb) in
Gfap expressing cells led to perinatal lethality and astrocytoma
development in mice [50]. In the transgenic mice presented here,
we have diagnosed the lesions as resembling human anaplastic
oligoastrocytomas WHO grade III because the neoplastic areas
had a marked Gfap+ astrocytic component, showed a diffuse
growth pattern and was accompanied by vascular proliferations,
similar to WHO grade III human gliomas. The neoplastic lesions
were not similar to grade IV glioblastomas and did not display
pallisading cells, necrosis or glomeruloid vascular structures.
In summary, this work indicates that overexpression of PDGF-
AL in brain has effects which differ in some important aspects from
previously reported studies on overexpression of PDGF-As and of
PDGF-B on a wild type background and in the worst cases results
in glioma-like lesions. However, it should be kept in mind that
because of differences in the promoters used and in transgene copy
numbers any direct comparisons between these transgenic lines
remain difficult. Further studies will be required to elucidate the
specific mechanisms by which overexpression of PDGF-AL in
brain promote a severe lethal phenotype, including neoplastic
lesions.
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Tissue analysis was partly performed at the KI/Karolinska University
Hospital-supported core facility for Mouse Tissue Analysis.
Figure 11. Ki67 in different areas of a transgenic mouse brain with glioma-like lesions. IHC for Ki67 in different areas of a transgenic
mouse brain (AL8, #4000) compared to similar areas in a wt mouse brain. Abbreviations: Hp-hippocampus, SVZ-subventricular zone, TL-temporal
lobe, LV-left ventricular wall, and Cblm-cerebellum.
doi:10.1371/journal.pone.0018303.g011
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